Výsledky vyhledávání - "Anfernee Hawkins"

Modulation of Estrogen α and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro

Autor: Kai Littlejohn, C. N. Orish, Anfernee Hawkins, Gustav Miranda-Carbon, Beverly Lyn-Cook, Rhonda Moore, Fatemeh Nouriemamzaden, Ebony Cotton, Beverly Word

Publikováno v: Anticancer Research. 40:3669-3683

BACKGROUND/AIM Triple negative cancer (TNBC) is a subtype of breast cancer that is highly aggressive, with poor prognosis and responds differently to treatments. This study investigated the role of vorinostat and indole-3-carbinol (I3C) on regulating

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57980655ba56a43b1369f947e80f0754
https://doi.org/10.21873/anticanres.14356

Zobrazit plný text záznamu

Abstract C109: Modulation of HDAC activity in subtypes of triple-negative breast cancer: Effects of vorinostat on HDAC 7 expression and cancer stem cells progression

Autor: Fatemeh Nouri Emamzadeh, Anfernee Hawkins, Rhonda Moore, Gustavo A. Miranda-Carboni, Beverly Word, Beverly D. Lyn-Cook

Publikováno v: Cancer Epidemiology, Biomarkers & Prevention. 29:C109-C109

Epigenetic drugs, such as histone deacetylase inhibitors (HDACi), are continuing to emerge as promising therapies for various cancers. These drugs, including FDA-approved vorinostat, are capable of multiple actions and considered to be multifunctiona

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45c035dc5c20aab2e0fc8f5f744c8b0e
https://doi.org/10.1158/1538-7755.disp18-c109

Zobrazit plný text záznamu

Abstract 5800: Vorinostat and indole-3-carbinol modulate microRNAs and histone deacetylase activity in subtypes of triple-negative breast cancer

Autor: Anfernee Hawkins, Beverly D. Lyn-Cook, George Hammons, Fatemeh Nouriemamzaden, Beverly Word

Publikováno v: Cancer Research. 78:5800-5800

Triple-negative breast cancer is a highly heterogeneous and aggressive subtype of breast cancer. Epigenetic drugs are continuing to emerge as promising therapies for triple-negative breast cancer (TNBC). These drugs, including the one used in this st

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4b956cd7c56ecb1ab1709b7dab2f2223
https://doi.org/10.1158/1538-7445.am2018-5800

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání